Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1997 1
1998 1
2002 1
2003 1
2004 1
2005 3
2006 9
2007 11
2008 9
2009 7
2010 7
2011 8
2012 12
2013 4
2014 6
2015 2
2016 5
2017 4
2018 4
2019 7
2020 6
2021 9
2022 9
2023 5
2024 7
2025 15
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

137 results

Results by year

Filters applied: . Clear all
Page 1
Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 study.
Andrade MO, Gutierres IG, Tavares MC, de Sousa IM, Balint FC, Marin Comini AC, Gouveia MC, Bines J, Madasi F, Ferreira RDP, Rosa DD, Santos CL, Assad-Suzuki D, de Souza ZS, de Araújo JAP, de Melo Gagliato D, Dos Anjos CH, Zucchetti BM, Ferrari A, de Brito ML, Cangussu R, Fernandes Monteiro MM, Hoff PM, Del Pilar Estevez-Diz M, Testa L, Barroso-Sousa R, Bonadio RC. Andrade MO, et al. Among authors: rosa dd. Breast. 2025 Oct;83:104473. doi: 10.1016/j.breast.2025.104473. Epub 2025 Apr 10. Breast. 2025. PMID: 40240201 Free PMC article.
Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study.
Bonadio RC, Tavares MC, Balint FC, de Sousa IM, Comini ACM, Madasi F, Bines J, Ferreira RDP, Rosa DD, Santos CL, de Souza ZS, Assad-Suzuki D, de Araújo JAP, Gagliato DM, Dos Anjos CH, Zucchetti BM, Ferrari A, de Brito ML, Cangussu R, Monteiro MMF, Hoff PM, Testa L, Estevez-Diz MDP, Barroso-Sousa R. Bonadio RC, et al. Among authors: rosa dd. Breast Cancer Res Treat. 2025 May;211(1):131-137. doi: 10.1007/s10549-025-07628-3. Epub 2025 Feb 3. Breast Cancer Res Treat. 2025. PMID: 39899161
Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 study.
Oliveira LJC, Rosa DD, Katz A, Assad-Suzuki D, Argolo D, Sanches SM, Testa L, Bines J, Kaliks RA, de Melo Gagliato D, Barroso-Sousa R, Corrêa TS, Shimada AK, Dos Anjos CH, Linck R, Megid TBC, Batista DN, Gomes DM, Cesca MG, Gaudêncio D, Moura LMA, Pereira de Araújo JA, Bonadio RC, Silva de Souza Z, Beal JR, Lopes MM, Sales LT, Parisi Marlière JLF, Mano MS. Oliveira LJC, et al. Among authors: rosa dd. Breast. 2025 Oct;83:104554. doi: 10.1016/j.breast.2025.104554. Epub 2025 Aug 5. Breast. 2025. PMID: 40768821 Free PMC article.
Germline Genetic Testing in Breast Cancer: Utilization and Disparities in a Middle-Income Country.
Souza ABA, Barrios C, de Jesus RG, Reinert T, Giacomazzi J, Rosa DD, Cronemberger E, Werutsky G, Bines J, Queiroz GS, Cordeiro de Lima V, Freitas-Junior R, Couto Filho JD, Emerenciano K, Resende H, Crocamo S, Van Eyll B, Neron Y, Dybal V, Lazaretti NS, Costamilan RC, Andrade DAP, Mathias C, Vacaro GZ, Borges G, Morelle AM, Sampaio Filho CA, Mano M, Lichtenfels M, Simon SD, Fay AP. Souza ABA, et al. Among authors: rosa dd. JCO Glob Oncol. 2025 Mar;11:e2400337. doi: 10.1200/GO-24-00337. Epub 2025 Mar 7. JCO Glob Oncol. 2025. PMID: 40053901
[Human papillomavirus and cervical neoplasia].
Rosa MI, Medeiros LR, Rosa DD, Bozzeti MC, Silva FR, Silva BR. Rosa MI, et al. Among authors: rosa dd. Cad Saude Publica. 2009 May;25(5):953-64. doi: 10.1590/s0102-311x2009000500002. Cad Saude Publica. 2009. PMID: 19488480 Free article. Review. Portuguese.
Trastuzumab (herceptin) for early-stage breast cancer.
Ismael G, Rosa DD, de Azambuja E, Braga S, Piccart-Gebhart M. Ismael G, et al. Among authors: rosa dd. Hematol Oncol Clin North Am. 2007 Apr;21(2):239-56. doi: 10.1016/j.hoc.2007.03.003. Hematol Oncol Clin North Am. 2007. PMID: 17512447 Review.
Real-World Data on First-Line Treatment of Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer in Brazil (BRAVE Study).
Werutsky G, Rosa DD, Reinert T, Barroso-Sousa R, Resende H, Signorini P, Cronemberger E, Fagundes JGM, Leal JHS, Guimarães MB, Vieira A, Weis LN, de Figueiredo JMB, Correa TS, Venero FC, Pauletto MM, Franche LMT, Bernardes MM, de Oliveira AHO, de Jesus RG, Gössling G, Bines J. Werutsky G, et al. Among authors: rosa dd. Clin Breast Cancer. 2025 Dec;25(8):e1040-e1049. doi: 10.1016/j.clbc.2025.05.020. Epub 2025 May 27. Clin Breast Cancer. 2025. PMID: 40581548 Free article.
137 results